these findings are relevant to programs designed to either prevent alloimmunization to the pla1 antigen ( through passive administration of anti-pla1 immunoglobulin to at-risk pla1-negative mothers ) , or to identify women at risk of delivery of thrombocytopenic infants ( by antenatal screening to detect women alloimmunized to the pla1 antigen ) .
C0948201
pla1
C0003320
antigen